Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis

Recruiting now

Conditions studied: Cystic Fibrosis

In brief

In the collective unconscious, a patient with cystic fibrosis does not smoke. This belief is so deeply rooted that there is virtually no French data on the prevalence of smoking among this vulnerable population. Faced with a cohort of patients undergoing a complete transformation (improved quality of life and life expectancy, fewer hospitalizations, reduced respiratory symptoms, better social integration), it is becoming urgent to assess the current situation in order to optimize tobacco prevention. This is all the more important given the emergence of international studies objectively examining the interactions between smoking, vaping, and the efficacy of Kaftrio.

Key facts

Study ID

NCT07342920

Run by

University Hospital, Strasbourg, France

People needed

100

Starts

2025-10-15

Expected to finish

2026-10-15

Last updated by the study team

2026-01-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patient (≥ 18 years old)
• With confirmed cystic fibrosis
• Regular follow-up at the Strasbourg Adult Cystic Fibrosis Center

You may not qualify if…

• Patients who have undergone a double lung transplant for cystic fibrosis.

Where it is running

• Service de Pneumologie - CHU de Strasbourg - France — Strasbourg, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.